HIV specialist and leading infectious diseases physician John G. Bartlett, MD, doesn’t mince words when you ask him about what his AIDS patients faced in the early days of the epidemic.
“They were the scourge of society – people didn’t like them because they were either gay or injection drug users, and there was a fear of contagion, that if you were in the same room with someone with AIDS you might get AIDS… They had diarrhea and dementia and wasting. It was an awful way to die. And besides that, everyone around you hated you. Can you imagine living to die that way?”
Dr. Bartlett became a ray of hope for people living with HIV/AIDS. He directed some of the first clinical trials of new treatments that prevent HIV from replicating, and pioneered the development of dedicated in-patient and out-patient medical care for HIV-infected patients.
In our third interview in a Science Speaks series commemorating 30 years of AIDS, Dr. Bartlett speaks frankly about hiding his treatment of AIDS patients from hospital administrators in the early ‘80s, key scientific breakthroughs over the years, and his views on the President’s Emergency Plan for AIDS Relief (PEPFAR) program moving forward.
In this guest blog post, Sophie Beauvais of the Global Health Delivery Project at Harvard University, and Chris Gilpin from the WHO’s Stop TB Department, summarize the ongoing virtual panel discussion on the feasibility of implementing the Xpert MTB/RIF in limited-resource settings. Discussion so far is highlighting the critical importance of understanding the local epidemiology for tuberculosis (TB), especially for multidrug-resistant TB (MDR-TB) and also for HIV-associated TB. Prioritizing these two risk groups in diagnostic algorithms that use the Xpert MTB/ RIF as the initial diagnostic test is a key message for the efficient integration of this new tool into existing health systems. But it is by no means the only key message. Read More…
Study results announced this morning unequivocally link early antiretroviral therapy (ART) for HIV-infected persons with a 96.3% less chance of transmitting the virus to an uninfected partner, as well as a decreased risk of contracting tuberculosis (TB), the number one killer of people living with HIV/AIDS. The National Institute of Allergy and Infectious Diseases (NIAID) […]
The surprisingly large and irregular practices of the private tuberculosis (TB) drug market could be driving treatment failures and the emergence of multi-drug resistance (MDR), according to a new report in the journal PLoS ONE. The study found the private TB drug market is now just as big as the public market, whereas previously TB […]
The following is an interview with Jeanne Gapiya, founding president of the Association Nationale de Soutien aux Séropositifs et aux Malades du SIDA (National Association for the Support of People Living with HIV/AIDS), or ANSS, in Burundi. Gapiya gave the opening address at the United Nations’ hearing for members of civil society in April in anticipation […]